Literature DB >> 18340479

Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

D Gomez1, S Farid, H Z Malik, A L Young, G J Toogood, J P A Lodge, K R Prasad.   

Abstract

BACKGROUND: This study was designed to evaluate the impact of an elevated preoperative neutrophil-to-lymphocyte ratio (NLR) on outcome after curative resection for hepatocellular carcinoma (HCC).
METHODS: Patients undergoing resection for HCC from January 1994 to May 2007 were identified from the hepatobiliary database. Demographics, laboratory analyses, and histopathology data were analyzed.
RESULTS: A total of 96 patients were identified with a median age at diagnosis of 65 (range, 15-85) years. The 1-, 3-, and 5-year overall survival rates were 80%, 58%, and 52%, respectively. Although the presence of microvascular invasion, NLR >or=5, and R1 resection margin were adverse predictors of overall survival, there were no independent predictors identified on multivariate analysis. The 1-, 3-, and 5-year disease-free survival rates were 74%, 63%, and 57%, respectively. Preoperative tumor biopsy, NLR >or= 5, multiple liver tumors, microvascular invasion, and R1 resection margin were all predictors of poorer disease-free survival. Multivariate analysis showed that a NLR >or= 5 and R1 resection margin were independent predictors of poorer disease-free survival. The median disease-free survival of those with a NLR >or= 5 was 8 months compared with 18 months for those with a NLR < 5.
CONCLUSION: Preoperative NLR >or= 5 was an adverse predictor of disease-free and overall survival.

Entities:  

Mesh:

Year:  2008        PMID: 18340479     DOI: 10.1007/s00268-008-9552-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  43 in total

1.  Guidelines for resection of colorectal cancer liver metastases.

Authors:  O J Garden; M Rees; G J Poston; D Mirza; M Saunders; J Ledermann; J N Primrose; R W Parks
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

2.  Large hepatocellular carcinoma: time to stop preoperative biopsy.

Authors:  Alastair L Young; Hassan Z Malik; Mohammed Abu-Hilal; J Ashley Guthrie; Judy Wyatt; K Rajendra Prasad; Giles J Toogood; J Peter A Lodge
Journal:  J Am Coll Surg       Date:  2007-06-27       Impact factor: 6.113

3.  Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis.

Authors:  Pedro Xavier; Luís Belo; Jorge Beires; Irene Rebelo; José Martinez-de-Oliveira; Nuno Lunet; Henrique Barros
Journal:  Arch Gynecol Obstet       Date:  2005-10-06       Impact factor: 2.344

4.  Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis.

Authors:  N Nagasue; T Ono; A Yamanoi; H Kohno; O N El-Assal; H Taniura; M Uchida
Journal:  Br J Surg       Date:  2001-04       Impact factor: 6.939

5.  Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

Authors:  W J Lesterhuis; I J M de Vries; D H Schuurhuis; A C I Boullart; J F M Jacobs; A J de Boer; N M Scharenborg; H M H Brouwer; M W M M van de Rakt; C G Figdor; T J Ruers; G J Adema; C J A Punt
Journal:  Ann Oncol       Date:  2006-04-06       Impact factor: 32.976

Review 6.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

7.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

9.  A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery.

Authors:  D C McMillan; H A Wotherspoon; K C Fearon; C Sturgeon; T G Cooke; C S McArdle
Journal:  Am J Surg       Date:  1995-10       Impact factor: 2.565

10.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

Authors:  C Fondevila; J P Metges; J Fuster; J J Grau; A Palacín; A Castells; A Volant; M Pera
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  157 in total

1.  Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Authors:  Shun-Jun Fu; Shun-Li Shen; Shao-Qiang Li; Yun-Peng Hua; Wen-Jie Hu; Li-Jian Liang; Bao-Gang Peng
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

2.  Preoperative Predictors Including the Role of Inflammatory Indices in Predicting Early Recurrence After Re-resection for Recurrent Hepatocellular Carcinoma.

Authors:  Yuxin Guo; Darren W Chua; Ye-Xin Koh; Ser-Yee Lee; Peng-Chung Cheow; Juinn-Huar Kam; Jin-Yao Teo; Pierce K Chow; Alexander Y Chung; London L Ooi; Chung-Yip Chan; Brian K P Goh
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

3.  The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.

Authors:  Akira Iwaku; Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Hirokazu Nishino; Masato Matsushima; Hisao Tajiri
Journal:  Med Oncol       Date:  2013-12-06       Impact factor: 3.064

4.  The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment.

Authors:  Mehmet Aliustaoglu; Ahmet Bilici; Bala Basak Oven Ustaalioglu; Volkan Konya; Murat Gucun; Mesut Seker; Mahmut Gumus
Journal:  Med Oncol       Date:  2009-10-22       Impact factor: 3.064

Review 5.  Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.

Authors:  Matteo Cescon; Valentina Rosa Bertuzzo; Giorgio Ercolani; Matteo Ravaioli; Federica Odaldi; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

6.  Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer.

Authors:  Mehmet Emin Ozyalvacli; Gulzade Ozyalvacli; Ramazan Kocaaslan; Kursat Cecen; Ugur Uyeturk; Eray Kemahlı; Adnan Gucuk
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

7.  Is the neutrophil to lymphocyte ratio associated with liver fibrosis in patients with chronic hepatitis B?

Authors:  Murat Kekilli; Alpaslan Tanoglu; Yusuf Serdar Sakin; Mevlut Kurt; Serkan Ocal; Sait Bagci
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

8.  Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma.

Authors:  Yukiyasu Okamura; Ryo Ashida; Takaaki Ito; Teiichi Sugiura; Keita Mori; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

9.  Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis.

Authors:  Hajime Aino; Shuji Sumie; Takashi Niizeki; Ryoko Kuromatsu; Nobuyoshi Tajiri; Masahito Nakano; Manabu Satani; Shingo Yamada; Shusuke Okamura; Shigeo Shimose; Hiroaki Sumie; Takuji Torimura; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-02-14

10.  Complete hemogram: simple and cost-effective in staging and predicting outcome in acute pancreatitis.

Authors:  Parmeshwar Ramesh Junare; Prasanta Debnath; Sujit Nair; Sanjay Chandnani; Suhas Udgirkar; Ravi Thange; Shubham Jain; Rahul Deshmukh; Partha Debnath; Pravin Rathi; Qais Contractor; Akshay Deshpande
Journal:  Wien Klin Wochenschr       Date:  2021-02-23       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.